Israeli cultivated meat producer Aleph Farms has raised $29 million in a funding round to expand production capacity and implement a revised biomanufacturing process. The round includes $22 million through a Simple Agreement for Future Equity (SAFE) and an additional $7 million from existing investors. The company expects to raise a further $10–15 million in the coming months as part of the same round.
“Aleph Farms is naturally adjusting its fundraising terms to align with 2025 market conditions”
The capital will support the expansion of Aleph’s pilot facility in Rehovot, Israel, and the development of intermediate-scale production sites in Europe and Asia. These new facilities are intended to operate under the company’s updated ‘1.2’ production platform, which combines cell proliferation and differentiation in a single bioreactor. The updated method removes the need for scaffolding and a secondary tissue bioreactor, enabling more efficient production of thicker whole-cut steaks.
As reported by AgFunderNews, Aleph Farms CEO and co-founder Didier Toubia said, “The funding will be used to scale up our pilot facility and launch the first Aleph Cut through an optimized production process designed for profitability and serving as a foundation for scaling the business globally.”
Aleph Farms reports a 97% reduction in production costs since 2020, attributing the decrease to a completed two-year R&D program. The company now targets production costs of $14 per pound at medium scale, with potential to reduce this further to $6–$7 per pound at larger scales. “We’re already working on an asset-light and very efficient way to scale up our process. This mitigates the financial risk of scaling up the business,” Toubia said in a recent Future of Foods interview with Alex Crisp.
Approvals & international expansion
The company is currently revising its regulatory filings in Israel, the United Kingdom, Switzerland, and Thailand to reflect its updated production method. Aleph has already received initial regulatory approval in Israel and plans to launch its cultivated beef products there within the next six months.
In Thailand, Aleph has partnered with biomanufacturing firms BBGI and Fermbox Bio to establish what it says is the country’s first production plant for cellular agriculture. A regulatory submission has already been filed, with approval anticipated by mid-2026.
Market correction presents investor entry point
While Aleph paused its US market entry plans two years ago, Toubia indicated that a return is expected in the next few years. “We see it as a long-term strategic market,” he told Future of Foods.
Commenting on the broader investment climate, Toubia noted in his AgFunderNews remarks that the cultivated meat sector is undergoing a correction. “Like our peers, Aleph Farms is naturally adjusting its fundraising terms to align with 2025 market conditions. That said, this adjustment presents a compelling entry point for new investors.”
